Covid-19 vaccine manufacturers will have to wait several months before the FDA decides whether to grant full approval, as opposed to the weeks it took to review data for an emergency use authorization.
“We’ll move as fast as we can, but we have to do the job correctly,” Peter Marks, director of the Center for Biologics Evaluation and Research at the Food and Drug Administration, said Thursday at a conference for FDA attorneys.
Pfizer Inc.
Learn more about Bloomberg Law or Log In to keep reading:
See Breaking News in Context
Bloomberg Law provides trusted coverage of current events enhanced with legal analysis.
Already a subscriber?
Log in to keep reading or access research tools and resources.